Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after 1,4-butanediol administration to healthy volunteers

被引:44
|
作者
Thai, D.
Dyer, J. E.
Jacob, P.
Haller, C. A. [1 ]
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, Div Clin Pharmacol, Dept Med, San Francisco, CA 94143 USA
[2] Amgen Corp, Thousand Oaks, CA USA
[3] Univ Calif San Francisco, California Poison Control Syst, Dept Clin Pharm, San Francisco, CA 94143 USA
关键词
D O I
10.1038/sj.clpt.6100037
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1,4-Butanediol (BD) is converted to gamma-hydroxybutyrate (GHB) after ingestion, and is associated with cases of dependence, coma, and death. The pharmacology of BD after oral ingestion has not been described in humans. Eight healthy volunteers (five men) were administered 25 mg/kg BD in a single oral dose after an overnight fast in a double-blinded, placebo-controlled, crossover study. Vital signs were monitored, and serial blood samples collected over 24 h for gas chromatography-mass spectrometry analysis of BD and GHB levels. Subjective mood and symptoms responses were assessed by visual analog scale. All subjects completed the study without significant adverse effects. BD was quickly absorbed and cleared, with time-to maximal plasma concentration of 24 +/- 12 min, and elimination half-life (T-1/2) of 39.3 +/- 11 min. BD was extensively converted to GHB, with a mean maximum GHB concentration of 45.6 +/- 19.7 mg/l reached 39.4 +/- 11.2 min after BD ingestion. GHB T-1/2 averaged 32.3 +/- 6.6 min. Some subjects exhibited slow oral clearance of BD, which tended to correlate with a variant haplotype of the alcohol dehydrogenase gene ADH-IB G143A. Mean CL/F was 151.5 +/- 176.5 ml/min kg for four subjects with variant haplotype versus 598.8 +/- 446.6 ml/min kg for four wild-type subjects (P = 0.061). Subjects reported feeling less awake and alert, less able to concentrate, and more lightheaded in the first 90 min after BD ingestion. Pulse oximetry readings were lower 45 min after BD dosing with a mean oxygen saturation of 98.5% with 1313 versus 99.6% with placebo (P = 0.031). Transient increases in mean systolic and diastolic blood pressure were observed, but other vital signs remained unchanged. BD was extensively converted to GHB after oral administration, but significant inter-individual variability in the rate of metabolism, possibly related to variants in ADH-IB, was observed. At the modest dose studied, significant clinical effects were not seen.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 50 条
  • [1] Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol
    Jain, AL
    Swadron, SP
    PEDIATRIC EMERGENCY CARE, 2001, 17 (04) : 314 - 315
  • [2] The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol
    Schep, Leo J.
    Knudsen, Kai
    Slaughter, Robin J.
    Vale, J. Allister
    Megarbane, Bruno
    CLINICAL TOXICOLOGY, 2012, 50 (06) : 458 - 470
  • [3] Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol - Response
    Quang, LS
    PEDIATRIC EMERGENCY CARE, 2001, 17 (04) : 315 - 316
  • [4] Fatal Overdose of Gamma-hydroxybutyrate Acid After Ingestion of 1,4-Butanediol
    Le Garff, Erwan
    Mesli, Vadim
    Cornez, Raphael
    Demarly, Christophe
    Tournel, Gilles
    Hedouin, Valery
    JOURNAL OF FORENSIC SCIENCES, 2018, 63 (01) : 326 - 329
  • [5] PYRAZOLE INHIBITION OF METABOLISM OF 1,4-BUTANEDIOL TO GAMMA-HYDROXYBUTYRATE IN RATS
    MCCABE, ERB
    BESSMAN, SP
    FEDERATION PROCEEDINGS, 1971, 30 (02) : A271 - &
  • [6] Recreational use of gammabutyrolactone and 1,4-butanediol, precursors of gamma-hydroxybutyrate
    Haramburu, F.
    Courne, M. A.
    Mathieu-Daude, J. C.
    Miremont-Salame, G.
    Daveluy, A.
    Boucher, A.
    Mallaret, M.
    Arditti, J.
    Djezzar, S.
    Gibaja, V.
    Sec, I.
    Le Boisselier, R.
    Peyriere, H.
    Fren, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 49 - 49
  • [7] 1,4-butanediol
    不详
    CHIMICA OGGI-CHEMISTRY TODAY, 1998, 16 (1-2) : 27 - 27
  • [8] The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans
    Bosch, Oliver G.
    Seifritz, Erich
    BRAIN RESEARCH BULLETIN, 2016, 126 : 47 - 60
  • [9] 1,4-butanediol
    Gopalan, SS
    CHEMISTRY & INDUSTRY, 1997, (08) : 288 - 288
  • [10] Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: A case report and review of the literature
    Shannon, M
    Quang, LS
    PEDIATRIC EMERGENCY CARE, 2000, 16 (06) : 435 - 440